Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin Knoch is active.

Publication


Featured researches published by Martin Knoch.


Expert Opinion on Drug Delivery | 2005

The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems

Martin Knoch; Manfred Keller

Inhalation of aerosols is the preferred route of administration of pharmaceutical compounds to the lungs when treating various respiratory diseases. Inhaled antibiotics, hormones, peptides and proteins are potential candidates for direct targeting to the site of action, thus minimising systemic absorption, dilution and undesired side effects, as much lower doses (as low as a fiftieth) are sufficient to achieve a similar therapeutic effect, compared with oral administration. A quick relief from the symptoms and a good tolerance are the main advantages of aerosol therapy. A new class of electronic delivery device is now starting to enter the market. The eFlow® electronic nebuliser (PARI GmbH, Germany) provides improved portability and, in some instances, cuts treatment time to only a fraction of what has been experienced with current nebulised therapy. Drug formulations and the device can be mutually adapted and matched for optimal characteristics to meet the desired therapeutic target. Reformulation of known and proven compounds in a liquid format are commercially attractive as they present a relatively low development risk for potential drug candidates and, thus, have become a preferred pathway for the development of new inhalation products.


Expert Opinion on Drug Delivery | 2006

New advances in aerosolised drug delivery: vibrating membrane nebuliser technology

Joseph S Lass; Andrew Jonathan Sant; Martin Knoch

Innovative nebuliser systems bear the potential to greatly improve and expand the administration of therapeutic aerosols for the treatment of respiratory diseases. Exploiting the technology of a microperforated vibrating membrane offers a close control of the droplet size that is being generated and targeted to reach the lower airways, with little oropharyngeal deposition, thereby reducing undesired side effects. The greatly improved efficiency of such devices, as exemplified by the eFlow® nebuliser (PARI), provides further advantages for the patient. A high respirable fraction due to the precisely defined perforations, low residual losses and the high liquid output rate combine to produce a highly efficient and fast administration of inhaled medications. Portability, ease of handling and noiseless operation have a positive effect on patient compliance, control of the therapy by the physician and the therapy costs.


Archive | 2007

Pulmonary delivery of alpha-1 proteinase inhibitor

Shabtai Bauer; Manfred Keller; Martin Knoch


European Respiratory Journal | 2017

Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack)

Carola Fuchs; Matthias Brosig; Matthias Finke; David Fiebig; Pravin Soni; Ahmet Tutuncu; Rod Saponjic; Martin Knoch


Archive | 2014

FLUID RESERVOIR FOR AN AEROSOL GENERATOR AND AEROSOL GENERATOR COMPRISING THE FLUID RESERVOIR

Thomas Gallem; Uwe Hetzer; Martin Knoch; Michael Neuner


European Respiratory Journal | 2011

Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal

Manfred Keller; Oliver Denk; Albert Bucholski; Martin Knoch


Archive | 2007

Administration pulmonaire d'un inhibiteur de la protéinase alpha-1

Shabtai Bauer; Manfred Keller; Martin Knoch


Archive | 2007

Pulmonale abgabe von alpha-i proteinase-hemmer

Shabtai Bauer; Manfred Keller; Martin Knoch


Archive | 2007

pulmonary delivery of a proteinase inhibitor alpha-1

Shabtai Bauer; Manfred Keller; Martin Knoch


Archive | 2000

Inhalationsvernebler Inhalation nebulizer

Martin Knoch; Manfred Keller; Roland Stangl; Thomas Gallem; Rainer Liening-Ewert; Markus Urich

Collaboration


Dive into the Martin Knoch's collaboration.

Top Co-Authors

Avatar

Manfred Keller

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Shabtai Bauer

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge